GLOW and KLOW: What a Certificate Means for a Peptide Blend

GLOW and KLOW are multi-peptide blends, and the question that comes up about both is the same one: what does a certificate of analysis mean when there are three or four compounds in the vial rather than one? It is a fair question, because a purity figure is a statement about a single target sequence, and a blend by definition has no single target. This article sets out what is in each blend, what the numbers in the names refer to, and how documentation for a blend differs from documentation for a single-compound vial.

What is in each

The number in the name is the total peptide content of the vial, not the quantity of any one component. GLOW 70mg is 70 mg because 10 plus 10 plus 50 is 70. KLOW 80mg is the same three components plus 10 mg of KPV. That is the entire difference between the two products: KLOW is GLOW with a fourth peptide added. Anyone comparing them on price should be comparing against that 10 mg of KPV and nothing else.

It is worth noticing the proportions, because they are not even. GHK-Cu is 50 of the 70 mg in GLOW and 50 of the 80 mg in KLOW. By mass, both blends are mostly copper peptide. This has a visible consequence: GHK-Cu is blue as the copper complex, and it dominates the appearance of the reconstituted blend well out of proportion to the number of components.

The components, by identity

Two of these are worth a second look. TB-500 is not thymosin beta-4. It is an acetylated seven-residue fragment corresponding to the 17 to 23 region of that protein, and at 889 g/mol it is a small fraction of the mass of the full protein. Suppliers who list TB-500 and thymosin beta-4 as the same line item are conflating two different materials. KPV is a tripeptide corresponding to the C-terminal three residues of alpha-MSH, which is why it sometimes appears in melanocortin-adjacent listings despite being sold here as a blend component.

What a certificate for a blend can and cannot establish

For a single-compound vial, a purity figure has an unambiguous meaning: of the peptide material present, this proportion is the target sequence. For a blend, that sentence does not parse, because there are three or four targets. Documentation for a blend answers a different set of questions, and the useful ones are these.

First, are the intended components present and identifiable? A chromatogram of a blend should resolve peaks attributable to each component. These four are well separated in size and in hydrophobicity, which helps; a seven-residue acetylated fragment, a fifteen-residue peptide, a copper-complexed tripeptide and a free tripeptide do not co-elute by accident under a competent method.

Second, is each component itself of the expected quality? That question is answered at the component level, before blending, on the material that goes into the vial. A blend assembled from characterized components inherits that characterization; a blend assembled from uncharacterized material cannot be rescued by testing the mixture afterwards, because a single chromatogram of four compounds is a harder document to interpret than four chromatograms of one compound each.

Third, the copper question applies here as it does to standalone GHK-Cu. Peptide purity by HPLC and copper content are separate determinations. A blend document that addresses the peptide components without addressing copper has characterized part of what is in the vial.

Documents for batches we have tested are published on the certificates of analysis page. A certificate is tied to a batch, so the cap and crimp colours on the vial are the reference point for finding it, and that matters here in particular, where two products share three components and differ by one. Coverage is partial: not every product and not every batch has a published certificate. Where testing has been done it is by HPLC together with purity testing, and the purity guarantee page is where the commitments and the explicit non-claims are set down.

Fixed ratio is the trade-off

The structural fact about any blend is that the ratio is set at the point of manufacture. A vial of GLOW contains BPC-157, TB-500 and GHK-Cu in a 1:1:5 ratio by mass and there is no operation that changes it. If the ratio is a variable in what you are doing, single-compound vials are the only arrangement that gives you control over it: BPC-157 10mg, TB-500 10mg and GHK-Cu 50mg or 100mg are all stocked separately. If the ratio is fixed by your design anyway, a blend is one vial, one batch and one document instead of three of each, which is a real reduction in record-keeping.

GLOW 70mg and KLOW 80mg sit under multi-peptide blends; the single-compound equivalents are under BPC-157 and TB-500 and copper peptides. Current pricing for all of them is on the Canadian price index, which is the practical way to work out whether the blend or the separate vials is the better arrangement for a given quantity.

In brief

GLOW is BPC-157 10 mg, TB-500 10 mg and GHK-Cu 50 mg. KLOW is those three plus KPV 10 mg. The number in the name is the total. Both are mostly copper peptide by mass, which is why they are blue. A blend certificate cannot report a single purity figure the way a single-compound certificate can, so the meaningful questions are component identification, component-level characterization before blending, and copper content as a separate determination. The ratio in a blend is fixed; if you need it variable, buy the components separately.

All compounds referenced here are supplied by ExoLabz for laboratory research use only. They are not for human or veterinary use, are not authorised by Health Canada as a drug or natural health product, and nothing on this page is guidance on preparation, administration or use.